The epidemiology of gastroenteropancreatic neuroendocrine tumors

Endocrinol Metab Clin North Am. 2011 Mar;40(1):1-18, vii. doi: 10.1016/j.ecl.2010.12.005.

Abstract

In this article, updated analyses of the National Cancer Institute Surveillance, Epidemiology and End Results (SEER) registry (1973-2007) are presented and compared with epidemiologic GEP-NET data from Europe and Asia. Several studies have demonstrated a steadily increasing incidence of GEP-NETs, and this escalation is still ongoing (SEER data 2004-2007). The common primary GEP-NET sites exhibit unique epidemiologic profiles with distinct patterns of incidence, age at diagnosis, stage, and survival. Overall, GEP-NET survival has improved over the past 3 decades, although the outcome for poorly differentiated tumors remains dismal.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Gastrointestinal Neoplasms / epidemiology*
  • Gastrointestinal Neoplasms / mortality
  • Humans
  • Incidence
  • Neuroendocrine Tumors / epidemiology*
  • Neuroendocrine Tumors / mortality
  • Pancreatic Neoplasms / epidemiology*
  • Pancreatic Neoplasms / mortality
  • SEER Program
  • Time Factors
  • United States / epidemiology